News | October 30, 2023
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
The companies plan to start a pivotal Phase 3 trial in the coming months
The companies plan to start a pivotal Phase 3 trial in the coming months
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Increased capability to produce medicines for challenging diseases including cancer
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Subscribe To Our Newsletter & Stay Updated
